North America Smart Inhalers Market By Product Type (Metered Dose Inhalers, Dry Powdered Inhalers, Nebulizers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease, Other Respiratory Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channels), Market Size, Segmental analysis, Country Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The North America Smart Inhalers market accounted for USD 0.73 Billion in 2024 and is expected to reach USD 3.35 Billion by 2035, growing at a CAGR of around 14.9% between 2025 and 2035. North America Smart Inhaler Market refers to highly technological inhaler devices that use digital ways to manage respiratory diseases, such as asthma and COPD. The inhalers track real-time data, and remind patients about the time for medication through their mobile app, thus making patients adhere to and engage with the treatment. The key market drivers are the rapidly rising prevalence of respiratory diseases, advancements in IoT and digital health, and an increase in focus on medication adherence. The main players involved in this market are pharmaceutical companies and the manufacturers of medical devices that bring innovations into this market. Overall, the market is growing rapidly because the healthcare sector is increasing its uptake of technology to improve the management of care for respiratory diseases.

Report Scope:

Market Dynamics

• Rising Demand for Effective Management Tools Amidst Growing Asthma and COPD Cases

The North American smart inhalers market is driven by several pivotal factors, including the increasing prevalence of asthma and COPD, which collectively affect millions of individuals in the region. According to the CDC, 25 million Americans are estimated to be affected with asthma, thus resulting in an enormous demand for proper management tools. Integrating health technologies into the healthcare system, with mobile applications and connected devices, increases patient compliance, and useful information is collected for healthcare providers to make better treatment decisions. Increased awareness about respiratory disease and the demand for individualized healthcare solutions increase the market's growth. Favorable government initiatives, which encourage better respiration through funding for research and public health campaigns, have also been conducive to innovation in smart inhaler technologies. All these factors come together to provide a very robust environment for the expansion of smart inhalers in North America.

• Telehealth Expansion Elevates Demand for Remote Monitoring Solutions, Including Smart Inhalers

The rise of telehealth services is a major driver of the North American smart inhalers market, as remote monitoring becomes increasingly essential for managing chronic respiratory conditions. With the onset of the COVID-19 pandemic, a need was portrayed for virtual health care, which makes the current requirement for the solutions of effective management from home. As per a report released by the CDC, telehealth visits increased by 154% during the pandemic, thereby pointing to an enormous shift in preference among patients. The smart inhalers have connectivity enabled on them. They enable providers in healthcare to monitor usage and adherence in real time. With this integration of technology, health improvement is ensured, and this sets patients above their condition by granting them power. Advances in telehealth will further increase demand for the use of remote monitoring tools, such as smart inhalers, to enhance their contribution to respiratory care further.

• Cost Barriers of Smart Inhalers Limit Accessibility for Some Patients

High-cost barriers are one of the major limiters for the North American smart inhaler market since advanced smart inhalers are often very much more expensive than traditional inhalers. Most of the patients will find it very difficult to afford those innovative devices, particularly the ones with limited or no insurance coverage. The American Lung Association conducted a research survey reporting that nearly 1 in 5 asthma sufferers encountered challenges in accessing their prescribed medications.

Such financial burden may limit the adoption of smart inhalers among patients and therefore restrict their potential benefits. Notably, the lack of reimbursement policies for smart inhalers adds complexity to access since many patients depend on insurance to pay for part of their care. These economic disadvantages might hinder the growth rate of the smart inhaler market, despite the possibility of positive advantages in patient management and health outcomes.

• Advancements in Smart Inhalers for Personalized Medication Delivery Based on Patient Needs

Advances in smart inhalers can be a huge opportunity for the North American market, mainly because the demand for personalized healthcare solutions continues to increase. Precision medicine allows for more individualized data-based prescription of doses by smart inhalers for better outcomes and treatment adherence. According to the NIH, nearly 73% of patients are interested in personalized treatment for chronic conditions management. In addition, developments in data analytics and artificial intelligence will also help in better monitoring of patient response and adjusting the delivery of medication promptly. Manufacturing companies, that have invested in developing smart inhalers, can ride on the trend of healthcare shifting towards a more personalized treatment. As the firms are busy upholding their large investments, this trend may contribute to improving outcomes and patient satisfaction, as well as boosting growth in the market.

• Integrated Inhalers Combining Medication Delivery with Health Monitoring Capabilities

Integrated inhalers that merge the delivery of medication with monitoring health capabilities will represent an opportunity for the North American smart inhalers market. The capacity to monitor respiratory health to that of medication use in data-oriented care can lead to more proactive management of chronic conditions. It is reported by the American Lung Association that 25 million Americans suffer from asthma, which is a big patient population that can profit from such innovations.

Integrated inhalers would lead to real-time data on an inhaler's usage and respiratory metrics in enhancing patient involvement in the treatment plans and adherence to the same. These devices also become valuable tools to improve communication between patients and healthcare professionals, allowing intervention in a timely and better care design, especially custom-made. Integration of inhalers is going to play a crucial role in changing the respiratory care scene and improving patient outcomes as the market for connected health solutions expands.

Industry Experts Opinion

“By working with Propeller’s existing partners to offer digital solutions for respiratory care pharmaceuticals and building on our proven ability to support digital solutions at scale, we can positively impact the lives of even more of the 380 million people worldwide who are living with this debilitating chronic disease.”

• ResMed CEO Mick Farrell

Segment Analysis

Based on product type, metered dose inhalers (MDIs) lead the North American smart inhalers market due to their ease of use and precise dosage delivery. Favored by asthma and COPD patients, MDIs drive innovation in smart technology, while dry powdered inhalers (DPIs) and nebulizers hold significant market shares due to their user-friendly designs and effective medication delivery. DPIs are breath-activated, while nebulizers provide continuous dosing, making them ideal for severe cases. Innovations in smart technology further enhance their appeal, attracting patients seeking better management of respiratory conditions.

Based on disease indication, the North American smart inhalers market focuses on asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. Asthma is the leading indication, primarily due to its high prevalence and the need for effective management tools. This drives demand for smart inhalers that enhance adherence and monitoring, while COPD also holds a substantial market share but does not surpass asthma's prominence. 

Regional Analysis

The United States primarily accounts for a significant share of North America's smart inhalers market, mainly because of the relatively high prevalence of asthma and COPD in this country. With more than 28 million Americans affected, demand for modern management tools that could improve patient adherence and monitoring is growing increasingly acute. The U.S. also boasts of the best healthcare infrastructure and substantial investments in research and development, making it an excellent environment for smart inhaler technology. The rapidly expanding telehealth services have increased the use of connected devices in real-time monitoring and personalized care for patients. All these, alongside governmental initiatives toward improved respiratory health, are contributing to the growth of this market, in which innovation is headed by collaborations between the tech industry and healthcare providers. Therefore, the US market is strong and suitable for continued growth and to fulfill growing needs for patients and for healthcare professionals.

The Canadian regional landscape of the North American smart inhalers market is characterized by increasing awareness related to respiratory diseases and a growing focus on innovative healthcare solutions. There are about 3.8 million Canadians who suffer from asthma, and in such situations, a rising demand for smart inhalers will come into play with effective management and adherence. The Canadian government also does its part in enhancing respiratory health by providing research funding and organizing public health movements toward better use of advanced inhaler technologies. A robust healthcare system with a patient-centric approach will also form an excellent base for the adoption of smart inhalers. Companies developing inhalers are partnering with companies that focus on technology to further enhance the smart inhalers. As a result, the market for smart inhalers is expected to grow considerably in Canada, following the global trends in digital health and personalized medicine as well.

Competitive Landscape

The competitive landscape of the North American smart inhalers market is dynamic, featuring key players such as ResMed, Philips Respironics, Teva Pharmaceuticals, and Adherium. Key players in North America smart inhalers market are ResMed, Philips Respironics, Teva Pharmaceuticals, and Adherium. Philips has developed connected inhaler solutions that offer real-time support for feedback and adherence tracking. Meanwhile, Teva Pharmaceuticals is preparing for partnership with the development of smart inhalers, incorporating digital health technologies into the management of the disease. Adherium also remains committed to the continued development of its adherence platforms. This factors competition as toughening these companies' research and development spend because demand grows for more effective respiratory management solutions.

North America Smart Inhalers Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2024, ResMed presented new research at the ATS 2024 conference, highlighting the effectiveness of Positive Airway Pressure (PAP) therapy. Conducted with leading scientists, the study underscores PAP's critical role in improving respiratory health outcomes.
• In April 2024, Teva Pharmaceuticals formed a clinical collaboration with Launch Therapeutics to expedite the development of their dual-action asthma rescue inhaler, ICS-SABA/TEV-248. Additionally, they secured a strategic funding agreement with Abingworth to support this initiative, underscoring their dedication to advancing asthma treatment solutions.

Report Coverage:

By Product Type

• Metered Dose Inhalers
• Dry Powdered Inhalers
• Nebulizers

By Disease Indication

• Asthma
• Chronic Obstructive Pulmonary Disease
• Other Respiratory Diseases

By Distribution Channel

• Hospital Pharmacies    
• Retail Pharmacies       
• Online Channels

By Region

North America

• U.S.
• Canada

List of Companies:

• ResMed
• Philips Respironics
• Teva Pharmaceuticals USA
• Adherium
• Cohero Health
• Sensory Technologies
• AstraZeneca
• GlaxoSmithKline
• Boehringer Ingelheim
• Novartis
• 3M Company
• Medtronic
• OMRON
• Rugby Laboratories
• Zywave

Frequently Asked Questions (FAQs)

---

Related Report